- Home
- QSI vs KROS Comparison
QSI vs KROS Comparison
Compare QSI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- KROS
- Stock Information
- Founded
- QSI 2013
- KROS 2015
- Country
- QSI United States
- KROS United States
- Employees
- QSI N/A
- KROS N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- KROS Health Care
- Exchange
- QSI Nasdaq
- KROS Nasdaq
- Market Cap
- QSI 219.8M
- KROS 558.9M
- IPO Year
- QSI N/A
- KROS 2020
- Fundamental
- Price
- QSI $2.11
- KROS $13.45
- Analyst Decision
- QSI Strong Buy
- KROS Buy
- Analyst Count
- QSI 3
- KROS 13
- Target Price
- QSI $2.38
- KROS $20.63
- AVG Volume (30 Days)
- QSI 8.4M
- KROS 603.2K
- Earning Date
- QSI 08-06-2025
- KROS 08-06-2025
- Dividend Yield
- QSI N/A
- KROS N/A
- EPS Growth
- QSI N/A
- KROS N/A
- EPS
- QSI N/A
- KROS 0.11
- Revenue
- QSI $3,443,000.00
- KROS $214,713,000.00
- Revenue This Year
- QSI $77.57
- KROS $5,006.76
- Revenue Next Year
- QSI $251.34
- KROS N/A
- P/E Ratio
- QSI N/A
- KROS $123.44
- Revenue Growth
- QSI 167.94
- KROS 91657.70
- 52 Week Low
- QSI $0.61
- KROS $9.12
- 52 Week High
- QSI $5.77
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- QSI 65.03
- KROS 43.42
- Support Level
- QSI $1.87
- KROS $13.24
- Resistance Level
- QSI $2.14
- KROS $13.77
- Average True Range (ATR)
- QSI 0.14
- KROS 0.38
- MACD
- QSI 0.02
- KROS -0.04
- Stochastic Oscillator
- QSI 93.65
- KROS 28.00
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.